Service

 

Our (e)Books and (e)Journals

IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.

Service

 

Moral Emotions, a Diagnostic Tool for Frontotemporal Dementia?

June 14, 2019 - Paris, France – A study conducted by Marc Teichmann and Carole Azuar at the Brain and Spine Institute in Paris, France and at the Pitié-Salpêtrière Hospital shows a particularly marked impairment of moral emotions in patients with frontotemporal dementia (FTD). The results, published in the Journal of Alzheimer's Disease, open a new approach for early, sensitive and specific diagnosis of FTD.

June 14, 2019

Specific Multinutrient Combination Benefits Patients with Early Stage Alzheimer’s Disease

June 12, 2019 - Amsterdam, NL – A new longitudinal study has shown that a nutritional drink* designated a "food for special medical purposes" containing the multinutrient combination Fortasyn Connect® can benefit patients with the earliest stages of Alzheimer's disease (AD), mild cognitive impairment, who are at risk of progressing to the dementia stage of AD, report scientists in the Journal of Alzheimer's Disease Reports.

June 12, 2019

Opioid Analgesics Increase the Risk of Pneumonia Among Persons with Alzheimer’s Disease

June 11, 2019 - Kuopio, Finland – Opioid analgesics were associated with a 30% increase in the risk of pneumonia in persons with Alzheimer's disease, a recent study from the University of Eastern Finland shows. The risk was most pronounced in the first two months of use. This is the first study to investigate the association between opioids and pneumonia in this population. The results were published in the Journal of Alzheimer's Disease.

June 11, 2019

Antihypertensive Drug Use Associated with a Decreased Dementia Risk in Almost 25,000 Elderly Persons Followed in General Practices in Germany

June 3, 2019 - Frankfurt, Germany – Various clinical trials indicate what effects can be expected from standardized intervention programs on the basis of existing evidence. Little is known about the way in which such programs can be implemented in actual care practice. However, it may be possible to use data from clinical practice to estimate the potential of drug prescriptions to delay or reduce the development of dementia.

June 3, 2019